Klotz, Laurence H <br/><br/>
A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.  [electronic resource] 

 -  European urology  May 2013 
 - 927-35 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-7560 
<br/><br/><label>Standard No.: </label>10.1016/j.eururo.2012.09.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Absorptiometry, Photon<br/>Administration, Oral<br/>Aged<br/>Aged, 80 and over<br/>Alendronate--administration & dosage<br/>Alkaline Phosphatase--blood<br/>Analysis of Variance<br/>Androgen Antagonists--administration & dosage<br/>Antineoplastic Agents, Hormonal--administration & dosage<br/>Biomarkers--blood<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--administration & dosage<br/>Canada<br/>Chi-Square Distribution<br/>Collagen Type I--blood<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Hip Joint--diagnostic imaging<br/>Humans<br/>Injections, Intramuscular<br/>Leuprolide--administration & dosage<br/>Lumbar Vertebrae--diagnostic imaging<br/>Male<br/>Middle Aged<br/>Osteoporosis--blood<br/>Patient Selection<br/>Peptides--blood<br/>Predictive Value of Tests<br/>Prostatic Neoplasms--drug therapy<br/>Time Factors<br/>Treatment Outcome